Case presentation & tygacil (tigecycline) usage
Kamel Al Mashaqi
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
General Surgery Resident, Jordan
Correspondence: Kamel Al Mashaqi, General Surgery Resident (PGY 4), TIH, Jordan
Received: June 25, 2015 | Published: August 14, 2015
Citation: Mashaqi KAI. Case presentation & tygacil (tigecycline) usage. MOJ Surg. 2015;2(4):87-91. DOI: 10.15406/mojs.2015.02.00026
Download PDF
- 24 year’s old, male, and medically free, from Yemen.
- Admitted on 8/4/2014
- With a 1-month Hx. of Gunshots to Chest/Abdomen that was operated on in Yemen.
- After 1-month post laparotomy + Lt Nephrectomy + Splenectomy + Rt Nephrostomy + Tracheostomy patient.
- Was treated with unknown medications & unknown antibiotics.
O/E
- CAO* 3
- Temp 37.5 – Pulse 125/m – RR 16/m – BP 123/70 – O2% 97%
- Ill Looking, cachectic, Pale, Jaundiced.
- Tracheostomy in situ.
- Bilateral Harsh Breathing Sounds + Decreased AEB.
- Soft Abdomen with previous midline incision of previous surgery & 3 drains:-
- Lt UQ à Bile
- Rt Loin à Urine
- Lt Loin à Empty Figure 1 & Table 1
Admission Labs
Lab |
Value |
Lab |
Value |
CRP |
58.9 ↑ |
Urine Analysis |
Prt + 1 |
ESR |
44 ↑ |
|
Glu + 3 |
PO4 |
4.3 |
|
Bld + 3 |
Mg |
1.42 ↓ |
|
Pus - Numerous |
Ca |
9 |
|
Red - Numerous |
Nasal Cx |
Acinetobacter |
Bld Cx |
-ve |
Sputum Cx |
Acinetobacter |
Urine Cx |
-ve |
Additional Admission Labs
Chest + abdomen + pelvic CT scan (oral contrast)
- Bilateral pleural effusion & more on RT side associated with atelectasis & ground glass opacities bilaterally with peri-bronchial thickening & LT fissural effusion.
- Translucent tubular shadow from LT lung extending to the SC tissue (fistula). Drainage tubes in upper abdomen (1st one @ porta hepatis, 2nd one @ sub diaphragmatic region).
- Ascites.
- Double J Catheter in RT Kidney -UB.
Management of case
- NPO + IV Fluids (Resuscitation)
- TPN Protocol
- I/O Charting
- Bld + Urine + Sputum + Nasal Cx
- Labs & Radiology (CXR+ Pan CT Scan + Nephrostogram)
- Pre-Op assessment & evaluation (PRBCs + FFP)
- Contact Isolation
- IV Medications (Tygacil + Meropenem + Diflucan + Nexium + Clexane + Hydrocortisone + Perfalgan)
Consultations to
- Cardiologist
- Nephrologist
- Pulmonologist
- Urologist Surgeon
- Infectious Disease Specialist
10/4/2014 (2 days post admission)
1st Surgery (Redo exploratory laparotomy with LT thoracotomy approach)
- LT Lung decortication + LT Lung Bullet injury repair.
- Gastro-Pleuro-Cutaneous Fistula excision.
- Primary repair (double layer) of stomach.
- LT hemicolectomy + End Ileostomy formation.
- Feeding Jejunostomy Tube Insertion.
- Pancreatic Necrosectomy.
- LT Chest Tube + 2 free abdominal drains insertion.
10/4/2014 (2 days post admission)
1st Surgery (Urology Surgery)
- RT Ureteroscopy
- DJ Insertion
Post Op Day (0) to Day (3)
- Patient transferred back to ICU-Surgical with same pre-op management.
- Patient started on Enteral feeding by (Jejunostomy tube) with ensure milk.
- Patient remained (Tachycardiac + Feverish).
Post Op Day (4) - 14/4/2014
- We discovered wound dehiscence with fluid discharge from abdominal wound.
- 2nd Surgery (2nd laparotomy + Wound Repair with Component separation closure technique).
- Tissue Cultures obtained & (+ve for Staphylococcus spp – Coagulase Negative) & ONLY sensitive to tigecycline.
Post Op Day (4) - 14/4/2014
- Patient transferred back to ICU-Surgical Intubated on Ventilator (atelectasis of LT lung & poor expansion with bad ABG’s).
- Patient kept on same protocol (IV Fluids + TPN Protocol + Enteral feeding + I/O Charting + IV Medications (Tygacil + Meropenem + Diflucan + Nexium + Clexane + Perfalgan).
- We added (Octreotide) to our list of medications for 5 days.
- Patient remained (Tachycardiac + Feverish).
Post Op Day (10) - 20/4/2014
- We discovered (by clinical & radiological evidence) a leak at the site of feeding Jejunostomy tube.
- 3rd Surgery (laparotomy + Repair).
- Same Pre-Op management but stopped the enteral feeding for few days.
- Patient remained (Tachycardiac + Feverish).
Post op day (18) - 28/4/2014
- Patient fully extubated with Spontaneous Breathing after several trials over the past few days.
- Multiple interval blood & other Cx came back –ve.
- Oral fluid feeding resumed for the 1st time from initial trauma with success.
- Vital signs were near NORMAL for 48 hours.
- Patient was able to ambulate for 1st time from initial trauma.
Post op day (19) - 29/4/2014
- Ventilator stopped & Tracheostomy removed.
- Tygacil with Meropenem stopped & patient Started on Piperacillin/Tazobactam.
- Kept on Vancomycin.
- Stopped feeding by Jejunostomy tube.
- Kept in ICU – Surgical with oral fluid feeding & observation of multiple spikes of fever & Tachycardia.
Post op day (23) - 03/05/2014
- Jejunostomy feeding tube removed.
- CT Chest/Abdomen/Pelvis (Normal Study).
- Kept in ICU – Surgical with oral fluid feeding & observation of multiple spikes of fever & Tachycardia.
Post op day (24) - 04/05/2014
- Non ionic contrast meal (Normal Study).
Post op day (27) - 07/05/2014
- Piperacillin/Tazobactam changed to Tienam.
- TPN stopped & Full regular diet given.
- CT Pulmonary Angio done (Normal Study).
- Kept in ICU – Surgical with oral fluid feeding & observation of multiple spikes of fever & Tachycardia.
Post op day (32) - 12/05/2014
- Patient transferred to floor.
- Regular diet (High Protein) & Oral medications.
- Fully ambulating.
Post op day (44) - 24/05/2014
- Patient discharged home.
- Patient came back to near normal level of activity & independence.
- V/S was normal for > 48 hrs.
- WBC & CRP went down to near normal levels.
- All Cx came back –ve.
- All Radiological Studies came back as normal studies.
- 20 year’s old, male, and medically free, from Yemen.
- Admitted on 04/02/2014 – NO formal Hx – Per Reports
- With a 1-week Hx. of High Velocity Gunshots to Abdomen that was operated on in Yemen.
- After 1-week post laparotomy + 2 drains found inside abdominal cavity with multiple visceral injuries (liver/pancreas/duodenum/gastric/IVC vs. Portal??).
- Was treated with unknown medications & unknown antibiotics.
O/E
- CA but disoriented.
- Paraplegic
- Temp 37.2 – Pulse 120/m – RR 31/m – BP 132/90 – O2% 98%
- Ill looking, cachectic, Pale but NOT Jaundiced.
- Bilateral Harsh Breathing Sounds + Decreased AE @ Basal Rt.
- Tender Abdomen + previous midline incision of previous surgery + bullet inlet @ RT Para midline + outlet @ LT lumbar & 2 drains:-
Rt loin à Bile
Rt Loin à Bile Figure 2 & Table 2
Admission Labs
Lab |
Value |
Lab |
Value |
Mg |
1.9 ↓ |
Urine Analysis |
Prt + 1 |
Ca |
7.4 ↓ |
|
Glu + 1 |
|
|
|
Bld + 4 |
|
|
|
Pus - 4 -6 |
|
|
|
Red - Numerous |
Nasal Cx |
ESBL |
Bld Cx |
-ve |
Sputum Cx |
ESBL |
Urine Cx |
-ve |
Additional Admission Labs
- Chest + abdomen + pelvic CT scan (triple contrast)
Lumbosacral MRI
- L2 vertebral fracture with injury to cord.
Management of case
Intubation + Full Sedation
- NPO + IV Fluids (Resuscitation)
- TPN Protocol
- I/O Charting
- Bld + Urine + Sputum + Nasal Cx
- Labs & Radiology (CXR+ Pan CT Scan)
- Pre-Op assessment & evaluation (PRBCs + FFP)
- Contact Isolation
- IV Medications (Meropenem + Nexium + Clexane)
Consultations to
- Neurosurgeon
- Pulmonologist
- Infectious Disease Specialist
- ENT Surgeon
05/02/2014 (1 days post admission)
- 1st Surgery (Exploratory laparotomy) with
- Resection of distal stomach + duodenum + head of pancreas.
- Retroperitoneal exploration & evacuation of multiple bilomas.
- CBD Tube drainage.
- 2 free abdominal drains inserted with 2 VAC dressings.
- Multiple packs inserted.
- Findings (Type V complex pancreatic – duodenal injuries).
Post Op Day (0) to Day (2)
- Patient transferred back to ICU-Surgical with same pre-op management.
- Blood transfused with FFP in regular basis.
- Vancomycin added to Rx regimen.
- Sandostatin added to Rx regimen.
- Clexane changed to Hibor.
- Patient remained (Tachycardiac + Feverish).
Post Op Day (3) - 08/02/2014
- 2nd Surgery (Laparotomy + Removal of Packing + Gastrojejunostomy + choledochojejunostomy + pancreaticojejunostomy).
- Patient transferred back to ICU-Surgical Intubated on Ventilator.
- Patient kept on same protocol (IV Fluids + I/O Charting + IV Medications (Meropenem + Vancomycin + Nexium + Hibor).
- Patient remained (Tachycardiac + Feverish).
Post Op Day (7) - 12/02/2014
- 3rd Surgery (Wound Exploration + Debridement + Dressing + Removal of VAC Dressing).
- Sputum Cx (+ve for Acinetobacter)
Post Op Day (11) - 16/02/2014
- 4th Surgery (Wound Exploration + partial closure with vicryl mesh + component separation technique).
D/C drains (2)
Post Op Day (13) - 18/02/2014
- 5th Surgery (Exploratory Laparotomy + Retroperitoneal drainge of subpancreatic fluids + Dressing + progressive closure).
- Tissue Cx (+ve for Acinetobacter)
- Colistin added to the Rx regimen.
- Extubated on O2 mask.
- Patient remained (Tachycardiac + Feverish).
Post Op Day (15) - 20/02/2014
- Patient started on (Ensure Milk by NGT + Apple Juice).
Post Op Day (17) - 22/02/2014
- 6th Surgery (Closure of abdominal wall).
- Blood Cx (+ve for Acinetobacter) & Tygacil added to the Rx regimen.
- Re-intubated due to Respiratory Distress.
Post Op Day (18) - 23/02/2014
- Enteral feeding started.
- D/C Chest Tube.
- Meropenem stopped.
- Flagyl added to the Rx regimen.
- Patient remained (Tachycardiac + Feverish).
Post op day (20) - 25/02/2014
- 7th Surgery (Wound lavage under GA + Dressing).
- CXR à white LT lung due to collapse.
- Patient is still intubated.
- Blood Cx (-ve).
- Sputum Cx (+ve Acinetobacter).
- TPN Started.
- Patient remained (Tachycardiac + Feverish).
Post Op Day (22) – 27/02/2014
- Trial of Extubation à Failed.
- 8th Surgery (Tracheostomy + DUGA).
Post Op Day (24) – 01/03/2014
- D/C Ventilator.
- V/S was normal for > 48 hrs.
- All Cx came back –ve.
Post op day (26) - 03/03/2014
- Patient discharged to Yemen, AMA by MEDEVAC.
- Patient is considered a HIGH risk for non-professional management with risk of death but AMA.
Why tygacil?
- Tygacil (tigecycline) has in vitro activity against a wider range of pathogens
- Resistant Gram +v: Enterococcus faecalis (VRE), Enterococcus faecium (VRE), Staphylococcus aureus (MRSA), Staphylococcus epidermidis (MRSE)
- Resistant Gram –ve: Acinetobacter baumannii, E. Coli, Klebsiella pneumoniae, Stenotrophomonas maltophilia, Tygacil is not affected by (ESBLs).
- Atypicals: New- Legionella pneumophila.
Tygacil (tigecycline) has in vitro activity against a wider range of pathogens
- Anaerobes: Bacteroides (distasonis, fragilis, ovatus, thetaiotaomicron, uniformis, vulgatus), Clostridium perfringes, others
- Gram +ve: Enterococcus (avium, casseliflavus, faecalis, faecium, gallinarum), Staphylococcus (aureus, epidermidis, haemolyticus), Streptococcus (pyogenes, agalactiae, anginosus grp)
- Gram –ve: Aeromonas hydrophila, Citrobacter (freundii, koserr), Enterobacter (cloacae, aerogenes), E.Coli, Klebsiella (oxytoca, pneumoniae) Serratia marcescens, Pasteurella multocida
Tygacil (tigecycline) has in vitro activity against a wider range of pathogens
- Gram +ve: New- Streptococcus Pneumoniae, including cases with concurrent bacteremia
- Gram –ve: New- Haemophilus influenzae & Parainfluenzae (Figure 3 & Table 3).
|
Tygacil |
3rd 4th Cephalosporin |
Carbapenems |
Fluroquinolones |
Pipa/Tazo |
Gram +ve |
√ |
√ |
√ |
√ |
√ |
Gram -ve |
√ |
√ |
√ |
√ |
√ |
Atypicals |
√ |
0 |
0 |
√ |
0 |
Anaerobes |
√ |
0 |
√ |
0 |
√ |
R. Gram +ve |
√ |
0 |
0 |
0 |
0 |
R. Gram -ve |
√ |
0 |
√ |
0 |
0 |
Pseudomonas |
0 |
0 |
√ |
0 |
√ |
Why Tygacil?
- Clinical coverage: Expanded broad-spectrum coverage including resistant gram positive, resistant gram negative, and anaerobes
- Efficacy: Proven as empiric mono therapy in patients with cIAI.
- Dosing Regimen: Does not require dosage adjustments for patients with renal impairment regardless of severity. No adjustments with mild-to-moderate hepatic impairment.
- Drug Interactions: Low potential for drug-drug interactions
- Results: Efficacy in treatment
- Convenient: Q 12 hr dosing
IV Antibiotic choice
2009 Infectious diseases society of america guidelines for treatment of cIAI
Optimal dosing: To ensure maximum efficacy & minimal toxicity & to reduce antimicrobial resistance, for empiric Rx of cIAI, guidelines suggest 100 mg initial dose of tigecycline, followed by 50 mg every 12 hrs.
cIAI: community acquired infections: Guidelines recommend tigecycline as single-agent Rx for initial empiric Rx in adults with infections of mild-to-moderate severity & perforated or abscessed appendicitis.
Treatment duration: a) According to guidelines, antimicrobial therapy should be limited to 4-7 days, unless it is difficult to achieve adequate source control.
- The recommended duration of Rx with Tygacil for cIAI is 5 to 14 days.
The author declares no conflict of interest.